Sanofi (NASDAQ:SNY) Given Average Recommendation of “Hold” by Brokerages

Shares of Sanofi (NASDAQ:SNYGet Free Report) have received an average recommendation of “Hold” from the six research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $55.00.

SNY has been the subject of several analyst reports. JPMorgan Chase & Co. lowered Sanofi from an “overweight” rating to a “neutral” rating in a research note on Tuesday, December 5th. Morgan Stanley started coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target for the company. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th.

Check Out Our Latest Report on Sanofi

Sanofi Stock Performance

Shares of SNY opened at $49.75 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average price is $48.23 and its 200-day moving average price is $49.42. Sanofi has a 52 week low of $42.63 and a 52 week high of $57.82. The stock has a market cap of $125.85 billion, a P/E ratio of 21.08, a P/E/G ratio of 1.77 and a beta of 0.61.

Sanofi (NASDAQ:SNYGet Free Report) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. Equities research analysts anticipate that Sanofi will post 4.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently bought and sold shares of the company. Boston Partners lifted its stake in shares of Sanofi by 1.9% during the fourth quarter. Boston Partners now owns 13,032,746 shares of the company’s stock worth $648,617,000 after buying an additional 245,682 shares during the period. BlackRock Inc. increased its position in shares of Sanofi by 2.5% in the first quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock valued at $546,804,000 after buying an additional 249,619 shares in the last quarter. Morgan Stanley increased its position in shares of Sanofi by 19.3% in the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock valued at $374,513,000 after buying an additional 1,251,199 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Sanofi by 2.3% in the first quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock worth $260,697,000 after acquiring an additional 112,404 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in shares of Sanofi by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 4,503,957 shares of the company’s stock worth $223,982,000 after acquiring an additional 305,781 shares during the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

(Get Free Report

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.